Polymer-Linked Modified G-CSF Fc Complex for Neutropenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current G-CSF formulations used to treat neutropenia are unstable in the bloodstream and require frequent administration, leading to patient discomfort and suboptimal therapeutic outcomes due to rapid degradation by proteolytic enzymes.
Innovation Solution
A protein complex is developed by covalently linking modified human granulocyte-colony stimulating factor (hG-CSF) to an immunoglobulin Fc region via a non-peptidyl polymer, specifically at the N-terminus, to enhance stability and maintain serum concentration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If G-CSF is chemically attached to polymers such as polyethylene glycol to increase blood stability, then blood stability is improved, but the titer needed for optimal physiologic effect is dramatically reduced
Solution Approach 1:
The patent creates a composite protein complex consisting of G-CSF, a non-peptidyl polymer, and an immunoglobulin Fc region. This composite structure combines the stability-enhancing properties of polymer attachment with the high-titer advantages of Fc region engagement, resolving the contradiction between blood stability and effective titer.
Solution Approach 2:
The non-peptidyl polymer serves as an intermediary component that links G-CSF to the Fc region without causing the detrimental effects of peptidyl linkers. This intermediary structure enables stable attachment while preserving the biological activity and titer of the G-CSF molecule.
2Quantity of substance
If G-CSF is frequently administered to maintain blood concentration, then blood concentration is maintained, but patient suffering increases due to excessive administration
Solution Approach 1:
The patent employs partial action by attaching only a portion of the G-CSF molecule to the polymer-Fc complex, maintaining sufficient free G-CSF activity while extending circulation time. This allows for less frequent administration while maintaining therapeutic blood concentrations, reducing patient suffering.
Solution Approach 2:
The Fc region attachment enables continuous presence of G-CSF in the bloodstream by leveraging the long half-life of Fc-containing molecules. This continuous action maintains therapeutic blood concentrations without requiring frequent re-administration, thereby reducing patient burden.
3Stability of the object's composition
If G-CSF is chemically attached to polymers to increase blood stability, then blood stability is improved, but administration frequency must be optimized to achieve optimal therapeutic outcome
Solution Approach 1:
The patent changes the structural parameters of G-CSF by attaching it to a polymer-Fc complex, which fundamentally alters its pharmacokinetic properties. This parameter change extends blood half-life and stability, enabling less frequent administration while maintaining or improving therapeutic outcomes.
Solution Approach 2:
The composite protein complex combines G-CSF with polymer and Fc region components, creating a molecule with optimized pharmacokinetic properties. This composite structure achieves both enhanced blood stability and improved therapeutic efficacy through sustained release and prolonged circulation.
Data Source
AI summary
This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.